Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-02-24

FDA Approved: UMECLIDINIUM AND VILANTEROL ELLIPTA — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application from Prasco Laboratories for umeclidinium bromide and vilanterol trifenatate in the Ellipta inhaler. This expands the ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • UMECLIDINIUM AND VILANTEROL ELLIPTA (umeclidinium bromide and vilanterol triflate)

Snippet

SUPPL AP for UMECLIDINIUM AND VILANTEROL ELLIPTA (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE)